Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Febrile Neutropenia
66%
Antibiotics
45%
Procalcitonin
33%
Imipenem
33%
Cilastatin
33%
Relebactam
33%
Infection
32%
Cefepime
16%
SARS Coronavirus
13%
Adverse Event
11%
Infectious Agent
11%
Diseases
8%
Gastrointestinal Symptom
5%
Myalgia
5%
Sleep Disorder
5%
Extended Spectrum Beta Lactamase
5%
Lactam
5%
Penicillinase
5%
Piperacillin Plus Tazobactam
5%
Carbapenem
5%
Meropenem
5%
Antimicrobial Resistance
5%
Clinical Trial
5%
Medicine and Dentistry
Malignant Neoplasm
44%
COVID-19
33%
Postcovid Syndrome
33%
Antibiotics
33%
Imipenem/Cilastatin
33%
Relebactam
33%
Febrile Neutropenia
33%
Infection
29%
Severe Acute Respiratory Syndrome Coronavirus 2
18%
Sequela
18%
Cefepime
16%
Diseases
11%
Adverse Event
11%
Pathogen
11%
Myalgia
7%
Gastrointestinal Distress
7%
Sleep Disorder
7%
Extended Spectrum Beta Lactamase
5%
Lactam
5%
Penicillinase
5%
Carbapenem
5%
Antibiotic Resistance
5%
Piperacillin/Tazobactam
5%
Meropenem
5%
Arm
5%
Keyphrases
Cancer Patients
33%
Long COVID
33%
Imipenem-cilastatin-relebactam
33%
In Cancer
33%
Antibiotic De-escalation
33%
Post-acute Sequelae of SARS-CoV-2 Infection
23%
Acute COVID-19
14%
COVID-19 Disease
14%
MD Anderson Cancer Center
9%
Myalgia
9%
COVID-19 Diagnosis
9%
Common Symptoms
9%
Gastrointestinal Diseases
9%
Sleep Disturbance
9%
